The device, intended to counteract the effects of an opioid overdose, costs $4,500 for a pack of two. In 2014, a two-pack cost only $690, according to the report.
More than 30 U.S. senators on Wednesday sent a letter to Kaléo criticizing the device’s high list price and asking for more information on the company’s pricing strategies.
“Such a steep rise in the cost of this drug threatens to price-out families and communities that depend on naloxone to save lives,” the senators wrote in the letter. Many of the senators represent states deeply affected by the ongoing opioid epidemic.
Kaléo argues its patient assistance efforts, including large patient discounts and few out-of-pocket costs, justify the list prices for its products, reports Fortune.
More articles on supply chain:
Supply chain tip of the week: 9 questions to test your inventory management IQ
10 statistics on drug, device recalls in Q4
6 quotes from Pfizer CEO on Trump, drug prices and more
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
